Nepoxên amino acid ên ku ji bo proteîna synthesize tê bikar anîn
Kîtekîteya Hilbera
| NO | Wer | Cas na | Nîşana kalîteya key | |||
| Qiralîtî | Max. nehetkirin | Mayîna solvent total | Şilî | |||
| 1 | FMOC-β-Ala-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 2 | Fmoc-D-Ala-D-Ala-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 3 | Fmoc-β-Ala-D-Ala-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 4 | Fmoc-Arg (PBF) -Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 5 | Fmoc-β-Ala-arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 6 | Fmoc-D-Arg (PBF) -D-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 7 | Fmoc-β-Ala-D-Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 8 | Fmoc-Homoarg (PBF) -HoMoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 9 | Fmoc-β-Ala-Homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 10 | FMOC-ASN (TRT) -ASN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 11 | FMOC-β-Ala-ASN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 12 | FMOC-ASP (Otbu) -asp (Otbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 13 | Fmoc-β-Ala-ASP (Otbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 14 | Fmoc-cys (TRT) -cys (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 15 | Fmoc-β-ala-cys (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 16 | Fmoc-cys (ACM) -cys (acm) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 17 | FMOC-β-Ala-CYS (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 18 | FMOC-GLN (TRT) -gln (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 19 | FMOC-β-Ala-GLN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 20 | Fmoc-Glu (Otbu) -glu (Otbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 21 | Fmoc-β-Ala-Glu (Otbu) -oh.h2o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 22 | FMOC-β-ALA-GLY-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 23 | Fmoc-wî (TRT) -His (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 24 | Fmoc-β-ala-wî (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 25 | Fmoc-ile-ile-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 26 | Fmoc-β-Ala-ile-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 27 | Fmoc-Leu-Leu-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 28 | Fmoc-β-Ala-Leu-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 29 | Fmoc-D-Leu-D-Leu-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 30 | Fmoc-β-Ala-D-Leu-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 31 | Fmoc-lys (boc) -lys (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 32 | FMOC-β-ALA-LYS (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 33 | Fmoc-lys (veqetandî) -Ly (veqetandî) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 34 | Fmoc-β-ala-lys (veqetandî) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 35 | Fmoc-Met-Met-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 36 | Fmoc-β-ala-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 37 | FMOC-ORN (BOC) -ORN (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 38 | FMOC-β-Ala-orn (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 39 | Fmoc-Phe-Phe-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 40 | Fmoc-β-Ala-Phe-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 41 | Fmoc-D-Phe-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 42 | FMOC-β-ALA-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 43 | Fmoc-Pro-Pro-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 44 | Fmoc-β-Ala-Pro-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 45 | Fmoc-Ser (tbu) -ser (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 46 | Fmoc-β-Ala-Ser (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 47 | Fmoc-Ser (TRT) -ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 48 | Fmoc-β-Ala-Ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 49 | Fmoc-thr (TBU) -thr (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 50 | Fmoc-β-ala-thr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 51 | Fmoc-Trp (BOC) -TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 52 | FMOC-β-Ala-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 55 | Fmoc-Tyr (tbu) -tyr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 56 | Fmoc-β-Ala-Tyr (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 57 | Fmoc-D-Tyr (ET) -D-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 58 | FMOC-β-ALA-D-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 59 | Fmoc-Tyr (me) -tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 60 | Fmoc-β-Ala-Tyr (Me) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 61 | Fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 62 | Fmoc-β-Ala-Val-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 64 | FMOC-β-ALA-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 65 | Fmoc-β-Ala-Dab-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 66 | FMOC- (3- (2-Naphthyl) -d-ala) 2-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 67 | FMOC-β-Ala-3- (2-Naphthyl) -D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 68 | Fmoc- (3- (3-Pyridinyl) -d-ala) 2-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 69 | FMOC-β-ALA-3- (3-PYRIDINYL) -D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 70 | FMOC- (4-chloro-D-PHE) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 71 | FMOC-β-ALA-4-chloro-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 72 | FMOC- (D-4APH (TBUCBM)) 2-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 73 | FMOC-β-ALA-D-4AHS (tbucbm) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 74 | Fmoc-Aph (L-hor) -aph (L-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 75 | Fmoc-β-ala-aph (L-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 76 | Fmoc-lys (ipr, boc) -lys (ipr, boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 77 | FMOC-β-ALA-LYS (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 78 | Fmoc-β-Ala-Aeea-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 79 | Fmoc-Aib-Aib-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 80 | Fmoc-β-Ala-Aib-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 81 | Fmoc-ARR-OH | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 82 | H-ARG (PBF) -OH | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 83 | Fmoc-D-ARG-OH | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 84 | HD-arg (PBF) -OH | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 86 | H-Homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 87 | Fmoc-D-Homoarg-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 88 | HD-Homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 89 | Fmoc-ASN-OH | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 91 | FMOC-ASP-OH | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 92 | H-ASP (Otbu) -OH | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 93 | Fmoc-Cys-Oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 94 | H-CY (TRT) -OH | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 95 | H-cys (acm) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 96 | Fmoc-Gln-Oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 97 | H-GLN (TRT) -OH | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 98 | Fmoc-Glu-OH | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 99 | H-Glu (Otbu) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 100 | Fmoc-HIS-OH | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 101 | H-wî (TRT) -OH | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 102 | Boc-his-oh | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 103 | Fmoc-Lys-OH | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 104 | H-Lys (BOC) -OH | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 105 | H-lys (Dabeş) -OH | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 106 | Fmoc-orn-oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 107 | H-ORN (BOC) -OH | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 108 | Fmoc-Ser-Oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 109 | H-Ser (TBU) -OH | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 110 | H-Ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 111 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 112 | H-thR (TBU) -OH | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 113 | Fmoc-Trp-OH | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 114 | H-trp (BOC) -OH | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 115 | Fmoc-D-TRP-OH | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 117 | Fmoc-Tyr-Oh | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 118 | H-TYR (tbu) -OH | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 119 | Fmoc-D-Tyr-Oh | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 120 | HD-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 121 | H-TYR (me) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 122 | FMOC-D-4AH (CBM) -OH | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 123 | Hd-4aph (tbucbm) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 124 | Fmoc-Lys (IPR) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 125 | H-lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
Ji dor
Zîyanşûndedanî
Gentolex hilberên kalîteya mezin peyda dike, heke kalîteya hilberê ji hêla muwekîlê ve di çarçoveya pêwîst de bi delîlên têr ve hatî bilind kirin, em ê analîz û nirxandina pêwîst peyda bikin da ku prosedurên tezmînatê derxînin.
Çêkerî
Kapasîteyên hilberên dermanan gihîştine TONS Grade, kapasîteyên hilberên kîmyewî digihîje 100tons + pola.
Lêkolîn û Pêşveçûn
Her sal, plan heye ku ji hêla tîmê R & D ve hatî saz kirin da ku hilberên nû yên cûda pêşve bibe, dema ku armancên hatine danîn, her endamê tîmê dê bi berpirsiyariya KPI û bi siyaseta teşwîqê re derbas bibe.
